VN September 2025

Vetnuus | September 2025 13 Article The development of the first rabies vaccine by Pasteur successfully reduced the incidence of rabies, but the disease has not been eliminated because it is maintained in many animal reservoirs.3 Many researchers have attempted to produce an affordable and safe rabies vaccine, and the currently recommended inactivated rabies vaccine, adjuvanted with aluminium hydroxide gel, the most common adjuvant, which only induces T helper cell type 2 (Th2) immune responses.4 Therefore, new adjuvants are required to increase the immunogenicity of inactivated rabies vaccines. Various carbohydrates such as β-glucan, mannan, and monophosphoryl lipid A (MPLA) can activate the immune system and induce T helper cell type 1 (Th1) immune responses,5,6; therefore, they are attractive immune adjuvant candidates. They may be used alone or in combination with other adjuvants such as Alum. Carbohydrates can be readily metabolised or degraded in vivo and are less likely to generate long-term toxicity.7 With their biocompatibility, low toxicity and ease of modification, carbohydrates have been studied as carriers for antigen delivery,8 which can often induce immune cell targeting and provide self-adjuvanting activities for a successful vaccination. Mannan, a polysaccharide derived from the structure of plants as well as the cell wall of yeasts, fungi and bacteria, contains mostly a β-1,4-linked mannose backbone with a small number of β-1,6linked glucose and galactose side chain residues.9 The carbohydrate can be recognised through binding with mannose recognition lectins presented on macrophages and other immune cells, which activates the host immune system via a non-self-recognition mechanism.10,11 The recognition initiates a set of signal transduction events leading to cytokine secretion, complement activation and CD8+ T cell activation.12 Although natural carbohydrates can be applied as vaccine components directly,13 in many cases, chemical modification of carbohydrates and/or covalent conjugates of antigens and adjuvants is necessary for enhanced efficacy.14 This can be beneficial in multiple ways, such as prolonged circulation and controlled release, size-induced lymph node targeting, better immune recognition through multivalency, enhanced cell uptake and immune activation. Two strategies (oxidative or reductive) for linking mannan to Antigens have been investigated, which induced drastically different types of immune responses.15,16 The conjugation strategy has been applied in many studies, including vaccines against cancer and influenza, such as breast cancer antigen, Mucin1,17 PCV2 protein of porcine circovirus type 2 virus (PCV2),18 secreted listeriolysin O (LLO) protein of Listeria monocytogenes,19 and inactivated H1N1 influenza virus20 for investigation of the enhancement of the immune responses. Based on previous reports, our studies focused on the investigation of the inactivated rabies virus conjugated to oxidised mannan to its vaccine efficacy. MATERIALS AND METHODS 1. Cell, virus, and mice BHK-21 C13 cells, obtained from the Institute Pasteur (Alborz, Iran), were used in this study. Pasteur strain PV fixed rabies virus, adapted to grow in BHK-21 cells (PV/BHK-21) and provided by the Institut Pasteur (Alborz, Iran), was used throughout this study. All mice were outbred female SW1 sourced from the Research and Production Complex of Pasteur Institute of Iran (Alborz, Iran). All mouse work was conducted at the Animal Laboratory of the quality control department of the Research and Production Complex of Pasteur Institute of Iran (Alborz, Iran), in accordance with an animal ethics application approved by the Iranian Animal Ethics Committee. 2. Cell culture BHK-21 Cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen) supplemented with fetal Bovine serum (FBS; 5-10%; Invitrogen, USA) and tryptose phosphate (TP; 0.2-0.3% w/v; Invitrogen, USA). 3. Virus production and inactivation BHK-21 cells were infected by the rabies virus strain PV/BHK-21 at a cell concentration of 2-3×106 cells/mL, with a multiplicity of infection (MOI) equal to 0.1/cell in a 10-L bioreactor containing 7 L of DMEM (Invitrogen, USA), supplemented with tryptose phosphate (TP; 0.20.3% w/v; Invitrogen, USA). For the rabies virus production step, pH was maintained at 7.4, pO2 at 30% air saturation, agitation rate at 40 rpm and temperature at 37ºC. The cell suspensions were centrifuged at 750-850 g for 10 min, and the viral supernatants (harvests) were first clarified by filtration through a 0.8-micron filter and then inactivated by 3 mM of Binary ethyleneimine (BEI) (Sigma, USA). 4. Rabies-mannan conjugate Whole inactivated rabies was conjugated to oxidised mannan described in Stambas et al.19 Briefly, mannan (Sigma; USA) (1 mL of 14 mg/mL) in 0.1 M phosphate, pH 6.0, was oxidised with the addition of 0.1 M sodium periodate (100 μL in water) in the dark at 4ºC for 1 hr. The mixture was quenched with 10 µL ethandiol and reacted for a further 30 min as before. The oxidised mannan mixture was passed through a PD10 column (GE Biosciences) pre-equilibrated with 0.05 M bicarbonate, pH 9.0, to remove byproducts. The eluted 2 mL fraction of oxidised mannan (≈7 mg/mL) after void volume (2.5 mL) was collected. Each milliliter of the whole inactivated rabies virus bulk was separately reacted with 0.5 mg/mL Al (OH)3 gel (Croda; Denmark), 100 µg of filter-sterilized mannan (Sigma; USA), or 350 µg of filter-sterilized oxidized mannan for 16 h at 20ºC in 100 rpm and the resulting preparations were analyzed for its vaccine safety and potency. According to previous studies, the periodate oxidation condition for mannan was chosen such that aldehyde residues are generated from only a fraction of oxidised mannose units of the mannan, without affecting its C-type lectin binding activity.21 For a complex antigen such as a whole inactivated rabies virus, we expect the majority of conjugation of mannan aldehyde groups to take place only at the exposed amino groups, forming Schiff base linkages. 5. Inactivity test A 0.03 mL of the inactivated bulk rabies vaccine was intracerebrally administered to each of ten SW1 female mice, with body weights ranging from 11 to 15 g. The animals are observed for 21 days. If more than two animals die during the first 48 hours, the test is repeated. The vaccine complies with the test if, from day 3 to day 21 post-injection, the animals show no signs of rabies, and the immunofluorescence test carried out on the brains of the animals shows no indication of the presence of rabies virus.22 6. Safety test 1 mL of the formulated bulk rabies vaccine was injected intraperitoneally into each of eight female SW1 mice, each weighing 17-22 g. The animals are observed for 21 days. The animals are observed at least daily for 14 days. >>>14

RkJQdWJsaXNoZXIy OTc5MDU=